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Background: Oral azithromycin given during labour reduces carriage of bacteria responsible for neonatal sepsis,
including Staphylococcus aureus. However, there is concern that this may promote drug resistance.
Objectives: Here, we combine genomic and epidemiological data on S. aureus isolated from mothers and babies
in a randomized intra-partum azithromycin trial (PregnAnZI) to describe bacterial population dynamics and re-
sistance mechanisms.
Methods: Participants from both arms of the trial, who carried S. aureus in day 3 and day 28 samples post-
intervention, were included. Sixty-six S. aureus isolates (from 7 mothers and 10 babies) underwent comparative
genome analyses and the data were then combined with epidemiological data. Trial registration (main trial):
ClinicalTrials.gov Identifier NCT01800942.
Results: Seven S. aureus STs were identified, with ST5 dominant (n=40, 61.0%), followed by ST15 (n=11, 17.0%).
ST5 predominated in the placebo arm (73.0% versus 49.0%, P=0.039) and ST15 in the azithromycin arm (27.0%
versus 6.0%, P=0.022). In azithromycin-resistant isolates, msr(A) was the main macrolide resistance gene (n=36,
80%). Ten study participants, from both trial arms, acquired azithromycin-resistant S. aureus after initially har-
bouring a susceptible isolate. In nine (90%) of these cases, the acquired clone was an msr(A)-containing ST5
S. aureus. Long-read sequencing demonstrated that in ST5, msr(A) was found on an MDR plasmid.
Conclusions: Our data reveal in this Gambian population the presence of a dominant clone of S. aureus harbour-
ing plasmid-encoded azithromycin resistance, which was acquired by participants in both arms of the study.
Understanding these resistance dynamics is crucial to defining the public health drug resistance impacts of
azithromycin prophylaxis given during labour in Africa.
Introduction
Azithromycin, a second-generation broad-spectrum macrolide, is
used to treat infections such as pneumonia, middle ear infections
and sexually transmitted infections.1,2 It has also been used in
mass drug administration (MDA) campaigns to control trachoma
in several endemic countries in Africa.3–5 The impact of these MDA
campaigns has varied from one country to another.6–8 MDA with
azithromycin (MDA-Z) may have beneficial effects beyond
trachoma control, having been shown to reduce asymptomatic
pneumococcal carriage for at least 1 month,9 and all-cause mor-
tality in children.10,11 However, a concern is that MDA-Z has been
associated with an increase in the prevalence of macrolide-
resistant bacterial species, even after the administration of only a
single dose.12 The spread of these resistant bacterial populations
and the associated risk to regions that may implement MDA-Z are
not fully understood.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Staphylococcus aureus is regularly implicated as a species in
which azithromycin resistance emerges following MDA-Z cam-
paigns. In Papua New Guinea, the proportion of azithromycin-
resistant (azithromycinR) S. aureus was five times higher among
pregnant women treated with azithromycin than in those in the
control group.13 A study in rural Gambia showed that three annual
rounds of MDA-Z were associated with a long-term increase in the
prevalence of azithromycinR S. aureus. There are three recognized
types of acquired macrolide resistance mechanisms in S. aureus:
(i) methylation of the ribosomal target (erm gene);14,15 (ii) active
efflux [msr(A) gene];14,16,17 and (iii) inactivation of the macrolide
(mph/ere gene).18,19 In the absence of these genes, mutations in
ribosomal proteins have been implicated in macrolide resistance.20
As azithromycin is a synthetic analogue of erythromycin, it is
presumed that these resistance mechanisms are active against
both antimicrobials. However, molecular data confirming this
association are limited for azithromycin, in particular for the
efflux mechanism encoded by msr(A). Further, there are limited
data available on the distribution of these macrolide resistance-
encoding genes following public health interventions using
azithromycin.
A recent MDA-Z trial in The Gambia, the Prevention of Bacterial
Infections in Newborn (PregnAnZI) trial, a double-blinded placebo-
controlled trial in which oral intra-partum azithromycin (2 g) was
administered, showed that phenotypic resistance to azithromycin
was associated with S. aureus isolates harbouring msr(A) or erm(C)
genes.21 Public health interventions using antibiotics, in addition to
driving the emergence of resistance, may also greatly alter the
local molecular epidemiology of S. aureus. The distribution of dom-
inant MSSA clones in Africa is heterogeneous,22 and in The Gambia
there is currently a paucity of data on the prevalence of S. aureus
STs, although ST15 and ST5 have been most commonly
reported.23,24 The ST15 lineage in Africa has been reported to fre-
quently harbour genes encoding the Panton–Valentine leucocidin
(PVL) toxin (25.9%–90.0%) and enterotoxin A (22.0%–74.6%), sug-
gesting a potential for increased virulence in this lineage.22
The recent PregnAnZI trial was undertaken to assess the effi-
cacy of one oral dose of azithromycin administered to women dur-
ing labour in lowering bacterial carriage both in the mother and in
her newborn as a necessary step to reduce puerperal and neonatal
sepsis. The trial revealed that azithromycin treatment significantly
decreased carriage of S. aureus, group B Streptococcus and
Streptococcus pneumoniae, but increased the prevalence of
azithromycinR S. aureus, amongst the population of bacterial
isolates recovered during a 28 day follow-up period.12 However,
carriage of the latter was observed to wane in babies 12 months
after delivery.25
The primary aims of this study were to: (i) use genomics to char-
acterize the population of azithromycinR S. aureus recovered from
mothers and babies during a 28 day follow-up period; (ii) identify
the genetic mechanisms responsible for azithromycin resistance
in this population and their genetic context; and (iii) explore the
potential roles of clonal replacement and transmission of
azithromycinR S. aureus at an individual patient level.
Patients and methods
Additional Materials and methods are provided in the Supplementary data,
available at JAC Online.
PregnAnZI trial
The PregnAnZI trial was a Phase III, double-blind, placebo-controlled trial
where 829 pregnant women attending the labour ward received a single
oral dose (2 g) of azithromycin or placebo (ratio 1:1). The study protocol has
been described elsewhere.26 Participants were monitored for 8 weeks and
nasopharyngeal swabs were collected during the first 4 weeks of the follow-
up (day 0 for mothers and days 3, 6, 14 and 28 for mothers and babies).
Trial registration (main trial): ClinicalTrials.gov Identifier NCT01800942.
Ethics
The trial was approved by the Joint MRC/Gambia Government Ethics
Committee. Mothers of children signed informed consent.
Sample selection
To explore potential genetic diversity amongst azithromycinR S. aureus, we
stratified isolates collected at day 3 and day 28 into four groups (Figure 1).
Two groups were participants in the azithromycin treatment arm where an
azithromycinR S. aureus was recovered at both timepoints (group 1) or only
at day 28, with an azithromycin-susceptible (azithromycinS) S. aureus iden-
tified at day 3 (group 3). The other two groups represented the same micro-
biological division, but for samples recovered from participants assigned to
the placebo arm [azithromycinR S. aureus at day 3 and day 28 (group 2) or
azithromycinS S. aureus at day 3 and azithromycinR S. aureus at day 28
(group 4)]. A total of 17 participants (34 isolates) were selected from these
four groups. In addition, all S. aureus recovered from the above subjects at
other timepoints (days 0, 6 and 14) were included.
WGS and bioinformatic analyses
WGS was performed on the NextSeq 500 (Illumina) using 2%150 bp chem-
istry. One isolate (S80062MN28) was subjected to long-read sequencing on
the RS-II (Pacific Biosciences). Bioinformatic approaches and analyses
included assembly, annotation and comparative genomics. The global
S. aureus phylogeny was inferred using publicly available genomes.
Antibiotic resistance and virulence gene detection was performed using the
NCBI antimicrobial resistance database (ncbi: updated 20 September 2018)
and the virulence factor database (vfdb: updated 14 August 2018). All se-
quence data generated for this study have been made publicly available
through the European Nucleotide Archive, project accession PRJEB31151.
Cloning and transformation of erm(C) and msr(A) genes
An empty vector control and a vector containing erm(C) or msr(A) were
electroporated into an ST5 azithromycinS S. aureus strain (S70065MN00).
Colonies were screened to confirm the presence of either erm(C) or msr(A)
genes using PCR.
Bacterial conjugation
Duplicate conjugation experiments were performed using an azithromycin-
resistant donor strain (S80062MN28) and an azithromycin-susceptible re-
cipient strain (S70065MN00). Resistance profiles of donor, recipient and
transconjugants are described in Table S1.
Antimicrobial susceptibility testing
Phenotypic susceptibility to azithromycin and erythromycin was deter-
mined using Etest (bioMe´rieux), performed as per the manufacturer’s
recommendations.
Statistics
Fisher’s exact test was used to compare the prevalence of STs or macrolide
resistance genes between the azithromycin and placebo groups. A P value
Bojang et al.
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of 0.05 was used as the cut-off for statistical significance. All analyses were
done using STATA/SE v12.1 (https://www.stata.com/).
Results and discussion
Genomic characterization of the study population
A total of 66 S. aureus isolates recovered from 7 mothers and 10
babies were included in this study. Of the 66 isolates, half (n=33)
were recovered from the nine participants selected from the
azithromycin-treatment arm and the other half from the eight
participants selected from the placebo arm of the PregnAnZI trial.
In silico MLST of the 66 S. aureus isolates revealed seven different
STs: ST1 [and a novel ST1 single-locus variant (ST1-SLV)], ST5, ST8,
ST15, ST152 and ST669 (Table 1). Overall ST5 was the dominant
ST, representing 61.0% of isolates (n=40) recovered from 14 partic-
ipants, followed by ST15, representing 17.0% of isolates (n=11)
recovered from 7 participants. The prevalence of ST5 was higher in
the placebo arm (73.0% versus 49.0%, P=0.039), while the preva-
lence of ST15 was higher in the azithromycin treatment arm
(27.0% versus 6.0%, P=0.022). These finding are largely consistent
with previous molecular epidemiological data from The Gambia, in
which ST15 and ST5 were common STs identified in cases of both
Study participants
Azithromycin arm
414 Women (49.9%)
419 Babies (49.7%)
Placebo arm
415 Women (50.1%)
424 Babies (50.3%)
216 Women (52.0%)
320 Babies (75.5%)
At least 1 NPS positive for S. aureus
149 Women (36.0%)
173 Babies (41.3%)
65 Women (15.7%)
101 Babies (24.1%)
2 Women 3 Babies
n=10
More
samples
1 Woman 3 Babies
n=8
Woman or Baby from above if positive for S. aureus at any
other timepoints (day 0, day 6 and day 14)
n=32
Total number of S. aureus
n=66
2 Women 2 Babies
n=8
2 Women 2 Babies
n=8
Random selection All samples Random selection Random selection
1 Woman (0.2%)
3 Babies (0.7%)
18 Women (4.3%)
43 Babies (10.1%)
2 Women (0.5%)
4 Babies (0.9%)
79 Women (19.1%)
147 Babies (35.1%)
152 Women (36.6%)
271 Babies (63.9%)
AZMR day 3
AZMR day 28
Group 1
AZMS day 3
AZMR day 28
Group 3
AZMR day 3
AZMR day 28
Group 2
AZMS day 3
AZMR day 28
Group 4
At least 1 NPS positive for S. aureus
S. aureus positive at day 3 + day 28 S. aureus positive at day 3 + day 28
Figure 1. Flow chart showing the sample selection criteria from women and babies in the PregnAnZI trial. NPS, nasopharyngeal swab; AZMR, azithro-
mycin resistant; AZMS, azithromycin susceptible. Resistance Etest cut-off values: azithromycin8 mg/L.
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colonization and disease.23,24 Unlike previous reports of increasing
PVL positivity in the Gambian ST15 population,22 the lukFS genes
were only identified in the isolates representing ST1 and ST152
(Figure 2).
To explore the genetic relationships between isolates, a max-
imum likelihood (ML) phylogenetic tree was inferred for each ST
(excluding the ST1-SLV). In the case of ST1, ST8, ST152 and ST669,
each clone was recovered from a single participant and demon-
strated limited core SNP diversity (Figure 2). This finding suggested
that these participants maintained the same S. aureus clone over
the 28 day follow-up period. Only ST5 and ST15 were recovered
from multiple participants (n=14 and 7, respectively) and as a
group demonstrated core SNP diversity. Isolates of the same ST
recovered from the same participant, however, largely formed a
single, genetically distinct clade within both phylogenetic trees
(Figure 2). The median pairwise core SNP distance between isolates
recovered from the same participant was 2.5 (±16.4, range 0–85)
for ST5 and 104 (±61.2, range 0–125) for ST15; for isolates
Table 1. Distribution of STs and macrolide resistance amongst the study population
All samples Azithromycin treatment arm Placebo treatment arm
MLST all AZMR all AZMR all AZMR
ST5 14 (40) 14 (36) 6 (16) 6 (16) 8 (24) 8 (20)
ST15 7 (11) 1 (1) 5 (9) 1 (1) 2 (2) 0 (0)
ST1 1 (4) 0 (0) – – 1 (4) 0 (0)
ST669 1 (4) 1 (4) 1 (4) 1 (4) – –
ST8 1 (3) 0 (0) – – 1 (3) 0 (0)
ST152 1 (3) 1 (3) 1 (3) 1 (3) – –
ST1-SLV 1 (1) 1 (1) 1 (1) 1 (1) – –
AZMR, azithromycin resistant.
Data are shown as number of participants (number of isolates).
ST669
P030/6
P744/2
1
P773/4
1
ST5 ST8
ST1 (PVL+)
ST15
100
P120/4
P046/9
P597/4
P289/0
P420/0
P592/5
P263/1
P118/6
P471/8
P186/5
P593/6
P027/0(1)
P361/2(3)
100
1
ST152 (PVL+)
P009/9
1
Figure 2. Distribution and phylogenetic relatedness of participant isolates. Illustrated are ML phylogenetic trees for each ST identified in the study
population (excluding the ST1-SLV), inferred from whole-genome alignments. Branch tips are coloured based on phenotypic susceptibility to azithro-
mycin (blue=susceptible and red=resistant, as determined by Etest). Scale bar indicates the estimated substitutions per site. Isolates recovered from
the same participant are indicated by a larger circle, labelled with the participant ID and coloured based on the treatment arm to which the partici-
pant was assigned (purple=azithromycin and green=placebo). Participants with isolates representing multi-STs are connected by a dotted line.
Isolates belonging to ST1 and ST152 were found to harbour the PVL toxin-encoding gene, lukFS.
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recovered from different participants it was 95 (±34.2, range 0–200)
for ST5 and 115 (±24.1, range 9–136) for ST15. A potential clonal re-
placement event probably occurred in one participant (P046/9),
with the ST5 MSSA isolate recovered on day 3 having a pairwise core
SNP distance of 84 and 85 to the ST5 MSSA isolates recovered on
day 6 and 28, respectively (Figure 3, Dataset S3). Another two partic-
ipants (P027/0 and P0361/2) appeared to be involved in a potential
transmission event as the four ST5 MSSA isolates recovered from
these participants demonstrated a pairwise core SNP distance of3
(Dataset S3). There was no apparent clustering of participant iso-
lates based on the treatment received (Figure 2).
Genetic basis of azithromycin resistance
Of the 66 S. aureus isolates, 21 were phenotypically azithromycinS
and 45 azithromycinR as determined by Etest. None of the
azithromycinS S. aureus carried a known azithromycin resistance-
conferring gene, whereas all azithromycinR S. aureus were found
to carry either an erm(C) (n=9, 20%) or msr(A) (n=36, 80%) gene
(Figure 3), genes associated with macrolide resistance. Mutations
in genes encoding ribosomal proteins (rplD, rplV and 23S rRNA)
were investigated. Only two missense mutations were identified:
RplD A133D and RplD T145I. Neither has been previously reported,
and they were identified in four isolates carrying erm(C) (P471/8)
and one isolate carrying msr(A) (P027/0), respectively.
The two macrolide resistance genes are associated with different
phenotypes: carriage of msr(A) among staphylococci is associated
with phenotypic resistance to 14-membered (clarithromycin, dirith-
romycin and erythromycin) or 15-membered (azithromycin) ring
macrolides and streptogramin A, but susceptibility to 16-membered
ring macrolides.18 Carriage of erm genes in staphylococci is associ-
ated with a broader phenotypic resistance depending on whether
the gene is inducible or constitutively expressed. The former, often
referred to as iMLSB, mediates resistance to 14- and 15-membered
macrolides and streptogramin B, but susceptibility to 16-membered
macrolides and lincosamides, with a risk of constitutive expression
arising in vivo.18,27 The latter, denoted by cMLSB, mediates resistance
to all macrolide, lincosamide and streptogramin B antibiotics.18
The prevalence of each gene differed significantly when iso-
lates were grouped based on the intervention which the partici-
pant received (P=0.002). The erm(C) gene was carried by isolates
belonging to ST15, ST152, ST669 and the ST1-SLV, and were only
Azithromycin treatment arm
A
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R  
S.
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s 
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y 
3 
&
 2
8
A
ZM
S  
S.
 a
ur
eu
s 
da
y 
3 
&
A
ZM
R  
S.
 a
ur
eu
s 
da
y 
28
Day
P471/8 M 15 5m 5m 5m 5m
0* 3
0 1 1
P593/6 M 5m 5m 5m 5m
31 6
P009/9 B - 152e 152e 152e
22 2
P030/6 B - 669e 669e 669e669e
2 4 5
P027/0 B - 15 15 1* e5m
0
P289/0 B - 15 15 15e
2 104
P420/0 B - 15 15 5m5m
125 0
P046/9 B - 5m 5m 5m
84 1
6 14 28 Day
P186/5 M 5m 5m 5m 5m 5m
0* 3
11 2 4
P592/5 M 5 5m 5m 5m 5m
1613 8 5
P120/4 B - 5m 5m 5m
2 0
1
P263/1 B - 5m 15 5m
6 14 28
Day
P361/2 M 15 5m 5 5m
0* 3
3 1
P773/4 M 1 1 1 1 5m
02 1
P597/4 B - 5 5 5m5m
0 5 2
511
P744/2 B - 8 8 8 5m
6 14 28Day
P118/6 M 15 5m 5m
0* 3
0
6 14 28
Placebo treatment arm
Figure 3. Individual participant timelines. Illustrated are the isolate timelines for each participant selected for the study, grouped based on the selec-
tion criteria outlined in Figure 1. Each participant is indicated by their participant ID and the adjacent circles represent the isolates recovered from
samples taken prior to the intervention (day 0 for mothers) and following the intervention on days 3, 6, 14 and 28 (for mothers and babies). Isolate
circles are coloured based on the phenotypic susceptibility to azithromycin (blue=susceptible and red=resistant, as determined by Etest). The internal
number indicates the in silico MLST of the isolate and the superscript letter indicates the macrolide resistance gene detected, ‘m’ for msr(A) and ‘e’ for
erm(C). Black lines connecting adjacent isolates indicate that the same clone has probably been maintained, with the pairwise core SNP distance pro-
vided. Alternatively, gaps between adjacent isolates indicate a potential clonal replacement event. AZMR, azithromycin resistant; AZMS, azithromycin
susceptible.
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recovered from participants assigned to the azithromycin treat-
ment arm. Conversely, the msr(A) gene was exclusively associated
with ST5 MSSA isolates and was recovered from participants
assigned to either treatment arm (Figure 3). As both resistance
genes would provide protection against azithromycin, the factors
mediating the differences in the prevalence of each gene between
participants assigned to the different interventions are unclear.
This finding requires confirmation in a larger isolate dataset.
Genetic context of msr(A)
In the ST5 lineage identified in this study, msr(A) was found to be
located on an MDR staphylococcal plasmid (Figure 4).
pS80062MN28 is 41069 bp in length and demonstrates significant
similarity to the published S. aureus plasmid pJSA01 (accession
AP014922.1) (Figure 4).28 Plasmid pJSA01 carries two virulence
genes, a newly discovered enterotoxin (SE1) and the epidermal
cell differentiation inhibitor A (EDIN-A) encoded by ednA.28,29
Additionally, it carries genes encoding cadmium resistance
(cadXD) and biocide tolerance (qacBR).28 Plasmid pS80062MN28
was found to carry both putative virulence genes and cadXD, but
not qacBR, and contained a 12 kb region not present in pJSA01
(Figure 4). Approximately 9 kb of this region demonstrated signifi-
cant similarity to a putative S. epidermidis plasmid pSE95_1 (acces-
sion CP024438.1),30 and included msr(A) and the b-lactamase
resistance-encoding gene blaZ (Figure 4). In all msr(A)-harbouring
ST5 MSSA isolates, an 27 kb contig was identified, representing
the plasmid region that spans from the ISSau6-type transposase
upstream of cadXD to another copy upstream of SE1 (Figure 4),
suggesting that all isolates probably carried a pS80062MN28-like
plasmid.
To demonstrate that msr(A) was responsible for macrolide re-
sistance in the ST5 lineage, a copy of the gene was transformed
into a macrolide-susceptible ST5 isolate from the study collection
(S70065MN00), using vector pRAB11.31 Two allelic variants of
erm(C) [erm(C)_2 and erm(C)_13] were also tested.
Transformation of an empty vector did not result in a change in
azithromycin or erythromycin susceptibility in isolate
S70065MN00; however, transformation of any one of the three re-
sistance genes resulted in an increase in the azithromycin MIC
from 1.0 to >256 mg/L (Figure S1), the first time introduction
of msr(A) or erm(C) genes in a previously azithromycinS S. aureus
clinical isolate has been shown to result in azithromycin resistance.
All clinical S. aureus isolates carrying either the erm(C) or msr(A)
gene had similarly high MIC values as those shown in the cloning
experiment (MIC256 mg/L). The MIC values for all azithromycin-
resistant and -susceptible isolates are included in Dataset S1 (col-
umn F). WGS of transformants demonstrated no additional muta-
tions potentially contributing to azithromycin resistance.
Therefore, acquisition of msr(A), probably through uptake of the
plasmid, is responsible for macrolide resistance in the ST5 lineage.
Results of the bacterial conjugation experiment demonstrated
that the transfer of the msr(A)-containing resistance plasmid was
<1.06%10#14 between S. aureus, indicating a low frequency of
transmission.
Contextualization of the study population
To contextualize the Gambian isolates of this study with the global
population of S. aureus, an ML phylogenetic tree comprising 7126
publicly available S. aureus genomes together with the sequenced
isolates of this study was constructed, as well as subtrees of CC5
and CC15 (Figure 5). The subtree of CC5 isolates (Figure 5b) illus-
trated that the Gambian ST5 MSSA lineage identified in this study
represented a single monophyletic clade, consistent with local ex-
pansion of this clone. The most closely related isolate to this clade
Figure 4. Schematic for the structure of pS80062MN28. Illustrated is the structure of pS80062MN28 (central sequence PRJEB31151) with genes of
interest annotated. pS800262MN28 has been aligned with S. aureus plasmid pJSA01 (accession AP014922.1) and S. epidermidis plasmid pSE95_1 (ac-
cession CP024438.1). Connecting lines indicate sequences that share >99% nucleotide sequence homology, coloured red or blue if the sequence was
present in the same or reverse orientation, respectively.
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Figure 5. Phylogenetic contextualization of study isolates. (a) Illustrated is an ML phylogenetic tree for a global population of 7192 S. aureus iso-
lates. The Gambian isolates identified in this study are indicated by white circles located at the branch tips. (b) A subtree of CC5 isolates and (c) a
subtree of CC15 isolates. In both subtrees, branches with <85% support (approximate likelihood ratio test) are labelled with a red circle. The
Gambian isolates identified in this study are indicated by circles located at the branch tips, coloured based on phenotypic susceptibility to azithro-
mycin (blue=susceptible and red=resistant, as determined by Etest). Adjacent to each subtree is a vertical line of circles indicating the countries
from which the isolates were recovered (refer to key); the heatmap indicates the presence or absence of three macrolide resistance genes:
erm(C) (1), msr(A) (2) and mph/ere (3). The scale bar indicates the estimated number of core genome substitutions.
Drug-resistant S. aureus in The Gambia JAC
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was recovered from the UK (435 SNPs). Given the distribution of
macrolide resistance genes in this CC5 population (Figure 5b), there
is no clear source for pS80062MN28 in the Gambian ST5 lineage.
Therefore, it remains unclear if the MDA-Z trial promoted the ex-
pansion of this lineage (already carrying the plasmid) or provided
the necessary selection pressure for plasmid uptake from a cur-
rently unidentified source. The potential consequences of either
evolutionary mechanism are greater than simply increasing the
prevalence of azithromycin resistance in a region due to the co-
location of msr(A) with other resistance and virulence genes on the
plasmid. Therefore, the impact of pS80062MN28 carriage for bac-
terial fitness and pathogenicity requires further investigation.
Population dynamics of azithromycinR S. aureus carriage
As all participants were sampled at multiple and consistent time-
points following administration of either azithromycin or the pla-
cebo, it presented an opportunity to explore the S. aureus population
dynamics of each participant during the 28 day follow-up period.
The isolate timelines are illustrated in Figure 3. Amongst the 17 par-
ticipants, two common patterns were observed and reflected the
way in which isolates had been selected. First, if a participant carried
an azithromycinR S. aureus at day 0 or day 3 (representing early/pre-
intervention acquisition), the same clone was identified at day 28,
suggesting that it had been maintained regardless of ST or the mac-
rolide resistance gene identified during the 4 weeks post-
intervention. This pattern was observed in all nine participants in
groups 1 and 2 (Figure 3). Second, if a participant acquired an
azithromycinR S. aureus after day 3 (representing delayed acquisi-
tion), then the first azithromycinR clone acquired was an ST5 MSSA
harbouring msr(A). This pattern was observed in seven of the eight
participants in groups 3 and 4 (Figure 3). Further, this was also
observed in the two mothers from groups 1 and 2 in which an
azithromycinS S. aureus was recovered at day 0 (pre-intervention)
and an azithromycinR S. aureus at day 3 (Figure 3, P593/6 and P592/
5). In two participants, it appeared that the azithromycinR ST5 iso-
late recovered at day 6 was replaced by either an azithromycinS ST5
(P361/2) or an azithromycinS ST15 (P263/1) isolate at day 14, which
then switched back to the azithromycinR ST5 isolate at day 28
(Figure 3). This could represent repeated clonal replacement in these
participants, dual carriage of both clones (which would be missed by
this study as only a single colony was sequenced from each sample)
or, in the case of P361/2, in vitro plasmid loss. It is also unclear why
the four participants in group 3 only carry azithromycinS ST15 MSSA
prior to acquiring azithromycinR MSSA, whereas group 4 are more
varied (Figure 3). Again, this is possibly due to the small sample size
considered in this study or may reflect an unknown selection pres-
sure promoting short-term carriage of the azithromycinS ST15 clone
in participants assigned to the azithromycin treatment arm.
Collectively these isolate timelines suggest that participants
who received the azithromycin intervention either maintained the
azithromycinR MSSA, which they probably carried prior to the inter-
vention, or acquired one, replacing an azithromycinS ST15 MSSA,
with the resulting azithromycinR MSSA being of varied ST and carry-
ing either msr(A) or erm(C). In participants who received the pla-
cebo, only azithromycinR ST5 MSSA was acquired, replacing various
azithromycinS MSSA populations. There are multiple potential
explanations for this finding. The increased use of azithromycin
may have significantly altered the local molecular epidemiology of
S. aureus, favouring azithromycinR clones. When combined with
widespread transmission, this could explain the high prevalence of
the ST5 lineage if it additionally has a colonization advantage over
other azithromycinR clones. The absence of this lineage in the
babies sampled at 1 year post-intervention suggests that any col-
onization advantage, if indeed present, is only advantageous in the
presence of high azithromycin use. Without a snapshot of the mo-
lecular epidemiology of S. aureus in the catchment area prior to the
trial, limited conclusions can be drawn about the impact that the
trial has had on the S. aureus population and highlights the need for
such information prior to any subsequent MDA campaigns.
Conclusions
We have used comprehensive genomic analyses to reveal the dy-
namics of azithromycinR S. aureus colonization in mothers and
babies after azithromycin treatment or placebo. Plasmid-encoded
msr(A) in ST5 MSSA was the most common clone, being respon-
sible for most azithromycinR S. aureus acquisitions in both study
arms. These results provide critical information to inform a greater
understanding of the ecological impact of azithromycin prophy-
laxis on staphylococcal populations in Western Africa.
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